PE20020473A1 - USO COMBINADO DE INHIBIDORES DE ACETILCOLINESTERASA Y AGONISTAS INVERSOS DE GABAa PARA EL TRATAMIENTO DE TRASTORNOS COGNITIVOS - Google Patents
USO COMBINADO DE INHIBIDORES DE ACETILCOLINESTERASA Y AGONISTAS INVERSOS DE GABAa PARA EL TRATAMIENTO DE TRASTORNOS COGNITIVOSInfo
- Publication number
- PE20020473A1 PE20020473A1 PE2001001026A PE2001001026A PE20020473A1 PE 20020473 A1 PE20020473 A1 PE 20020473A1 PE 2001001026 A PE2001001026 A PE 2001001026A PE 2001001026 A PE2001001026 A PE 2001001026A PE 20020473 A1 PE20020473 A1 PE 20020473A1
- Authority
- PE
- Peru
- Prior art keywords
- gabaa
- treatment
- cognitive disorders
- naphthyridine
- carboxamide
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 3
- 239000000544 cholinesterase inhibitor Substances 0.000 title abstract 2
- 208000010877 cognitive disease Diseases 0.000 title abstract 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 1
- -1 C1-C6 ALKYL Chemical class 0.000 abstract 1
- 102000027484 GABAA receptors Human genes 0.000 abstract 1
- 108091008681 GABAA receptors Proteins 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 229940039856 aricept Drugs 0.000 abstract 1
- 229960003530 donepezil Drugs 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24114500P | 2000-10-17 | 2000-10-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020473A1 true PE20020473A1 (es) | 2002-06-14 |
Family
ID=22909428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001001026A PE20020473A1 (es) | 2000-10-17 | 2001-10-16 | USO COMBINADO DE INHIBIDORES DE ACETILCOLINESTERASA Y AGONISTAS INVERSOS DE GABAa PARA EL TRATAMIENTO DE TRASTORNOS COGNITIVOS |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20020151591A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1328294A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2004511512A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20030046509A (cg-RX-API-DMAC7.html) |
| AR (1) | AR030893A1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU9411701A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2426120A1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUP0302476A3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL155225A0 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ525103A (cg-RX-API-DMAC7.html) |
| PE (1) | PE20020473A1 (cg-RX-API-DMAC7.html) |
| UY (1) | UY26970A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002032412A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200302918B (cg-RX-API-DMAC7.html) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10119862A1 (de) * | 2001-04-24 | 2002-11-07 | Hf Arzneimittelforsch Gmbh | Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen |
| EP1581203A1 (en) * | 2002-12-24 | 2005-10-05 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US8299062B2 (en) * | 2003-09-17 | 2012-10-30 | Franklin Volvovitz | Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction |
| JPWO2005027968A1 (ja) * | 2003-09-19 | 2007-11-15 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ダウン症候群治療剤 |
| TW200533371A (en) * | 2004-04-15 | 2005-10-16 | Dainippon Pharmaceutical Co | Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative |
| WO2005112946A1 (en) * | 2004-05-14 | 2005-12-01 | The Johns Hopkins University | Method for improving cognitive function by co-administration of a gabab receptor antagonist and an acetylcholinesterase inhibitor |
| JP2008509212A (ja) * | 2004-08-09 | 2008-03-27 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 中枢神経系障害の治療のための新規なキノキサリノンノルエピネフリン再吸収阻害剤 |
| CN100382802C (zh) * | 2005-08-08 | 2008-04-23 | 赵德禄 | 治疗自主神经系统功能紊乱的药物 |
| WO2007139818A2 (en) | 2006-05-22 | 2007-12-06 | The Board Of Trustees Of The Leland Stanford Junior University | Pharmacological treatment of cognitive impairment |
| CA2954376C (en) * | 2006-10-16 | 2019-06-11 | Bionomics Limited | Novel anxiolytic compounds |
| US10954231B2 (en) | 2006-10-16 | 2021-03-23 | Bionomics Limited | Anxiolytic compounds |
| JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
| WO2008065141A1 (en) | 2006-11-30 | 2008-06-05 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
| ZA200905537B (en) | 2007-03-01 | 2010-10-27 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
| US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| EP2475428B1 (en) | 2009-09-11 | 2015-07-01 | Probiodrug AG | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
| EA037187B1 (ru) | 2010-02-09 | 2021-02-17 | Дзе Джонс Хопкинс Юниверсити | Способ и композиция для лечения когнитивного расстройства |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| NZ602312A (en) | 2010-03-10 | 2014-02-28 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| CA2818025A1 (en) | 2010-11-15 | 2012-05-24 | Agenebio, Inc. | Pyridazine derivatives, compositions and methods for treating cognitive impairment |
| CA2828780A1 (en) | 2011-03-02 | 2012-09-07 | Bionomics Limited | Novel small-molecules as therapeutics |
| JP6050264B2 (ja) | 2011-03-16 | 2016-12-21 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
| JP6055817B2 (ja) | 2011-05-12 | 2016-12-27 | バイオノミックス リミテッド | ナフチリジンの調製方法 |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| US10806717B2 (en) | 2013-03-15 | 2020-10-20 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| AU2014228512A1 (en) | 2013-03-15 | 2015-10-01 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| EP4032889A1 (en) | 2013-12-20 | 2022-07-27 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| WO2016191288A1 (en) | 2015-05-22 | 2016-12-01 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| CA2990004C (en) | 2015-06-19 | 2024-04-23 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| BR112019012821A2 (pt) | 2016-12-19 | 2019-11-26 | Agenebio, Inc. | derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo |
| US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
| AU2019288382B2 (en) | 2018-06-19 | 2024-07-25 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| AU2023324882A1 (en) | 2022-08-19 | 2025-03-20 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4374138A (en) * | 1981-11-13 | 1983-02-15 | Warner-Lambert Company | Antibacterial amide compounds, compositions, and methods of use |
| US5870723A (en) * | 1994-11-28 | 1999-02-09 | Pare, Jr.; David Ferrin | Tokenless biometric transaction authorization method and system |
| US6088683A (en) * | 1996-08-21 | 2000-07-11 | Jalili; Reza | Secure purchase transaction method using telephone number |
| US6016476A (en) * | 1997-08-11 | 2000-01-18 | International Business Machines Corporation | Portable information and transaction processing system and method utilizing biometric authorization and digital certificate security |
| HUP0003258A3 (en) * | 1997-08-25 | 2001-05-28 | Neurogen Corp Branford | Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands |
| US6143760A (en) * | 1997-08-25 | 2000-11-07 | Neurogen Corporation | Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands |
| GB9805561D0 (en) * | 1998-03-16 | 1998-05-13 | Merck Sharp & Dohme | A combination of therapeutic agents |
-
2001
- 2001-10-12 US US09/976,347 patent/US20020151591A1/en not_active Abandoned
- 2001-10-15 NZ NZ52510301A patent/NZ525103A/xx unknown
- 2001-10-15 AU AU9411701A patent/AU9411701A/xx active Pending
- 2001-10-15 WO PCT/IB2001/001934 patent/WO2002032412A2/en not_active Ceased
- 2001-10-15 AR ARP010104836A patent/AR030893A1/es unknown
- 2001-10-15 HU HU0302476A patent/HUP0302476A3/hu unknown
- 2001-10-15 EP EP01974604A patent/EP1328294A2/en not_active Withdrawn
- 2001-10-15 JP JP2002535650A patent/JP2004511512A/ja active Pending
- 2001-10-15 IL IL15522501A patent/IL155225A0/xx unknown
- 2001-10-15 KR KR10-2003-7005292A patent/KR20030046509A/ko not_active Ceased
- 2001-10-15 AU AU2001294117A patent/AU2001294117B2/en not_active Ceased
- 2001-10-15 CA CA002426120A patent/CA2426120A1/en not_active Abandoned
- 2001-10-16 PE PE2001001026A patent/PE20020473A1/es not_active Application Discontinuation
- 2001-10-16 UY UY26970A patent/UY26970A1/es not_active Application Discontinuation
-
2003
- 2003-04-11 ZA ZA200302918A patent/ZA200302918B/en unknown
-
2004
- 2004-08-06 US US10/912,993 patent/US20050009861A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0302476A2 (hu) | 2003-11-28 |
| CA2426120A1 (en) | 2002-04-25 |
| WO2002032412A3 (en) | 2003-03-20 |
| US20020151591A1 (en) | 2002-10-17 |
| KR20030046509A (ko) | 2003-06-12 |
| NZ525103A (en) | 2004-12-24 |
| UY26970A1 (es) | 2002-06-20 |
| AR030893A1 (es) | 2003-09-03 |
| EP1328294A2 (en) | 2003-07-23 |
| AU2001294117B2 (en) | 2006-07-27 |
| IL155225A0 (en) | 2003-11-23 |
| HUP0302476A3 (en) | 2005-05-30 |
| WO2002032412A2 (en) | 2002-04-25 |
| ZA200302918B (en) | 2004-04-13 |
| US20050009861A1 (en) | 2005-01-13 |
| AU9411701A (en) | 2002-04-29 |
| JP2004511512A (ja) | 2004-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020473A1 (es) | USO COMBINADO DE INHIBIDORES DE ACETILCOLINESTERASA Y AGONISTAS INVERSOS DE GABAa PARA EL TRATAMIENTO DE TRASTORNOS COGNITIVOS | |
| NO324217B1 (no) | Kondenserte azepinderivater og deres anvendelse som antidiuretiske midler | |
| AR034669A1 (es) | Derivados de tetrahidroquinolina y su uso para controlar la fertilidad | |
| PE20011114A1 (es) | Decahidro-isoquinolinas | |
| DK1337518T3 (da) | Piperazinylpyrazinforbindelser som antagonister for serotonin-5-HT2-receptoren | |
| MA28432B1 (fr) | Antagonistes du recepteur de la chimiokine | |
| LV11617A (lv) | Morfolins un tiomorfolins ar tahikinina receptoru antagonistu ipasibam | |
| HRP20090195T1 (hr) | Inhibitori mitotičkih kinezina | |
| HUP0301045A2 (hu) | Kinolinonszármazékok mint tirozin kináz inhibitorok, ezeket tartalmazó gyógyszerkészítmények | |
| BR0012489A (pt) | Composto, composição farmacêutica, uso de um composto, e, kit para a contracepção masculina | |
| PE20040512A1 (es) | Compuesto de pirazol-pirimidina anilina | |
| CO5310534A1 (es) | Nuevos derivados de androstano anti-inflamatorios | |
| MA30756B1 (fr) | Derives de cinnamoyl-piperazine et leur utilisation comme antagonistes par-1 | |
| MA31761B1 (fr) | Nouveaux inhibiteurs de seh et leur utilisation | |
| BR9810544A (pt) | Derivados de azetidinilpropilpiperidina, intermediários e uso como antagonistas de taquicinina | |
| AR035756A1 (es) | Uso de carbamatos en la preparacion de medicamentos para la prevencion o tratamiento de trastornos neurodegenerativos | |
| PA8561501A1 (es) | Lactamas como antagonistas de taquiquininas | |
| NO20033959L (no) | Benzimidazoler som er nyttige i behandling av seksuell dysfunksjon | |
| NO983178L (no) | Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasaytisk preparat for behandling eller profylakse av menopausesymptomer | |
| PE20001461A1 (es) | Compuestos derivados de 3,16-dihidroxi-estra-1,3,5(10)-trieno, empleo de los mismos y de partes estructurales de los mismos y composiciones farmaceuticas que los contienen | |
| PE20021018A1 (es) | DERIVADOS DE ß - CARBOLINA | |
| ATE308540T1 (de) | Antithrombosemittel | |
| PE20061147A1 (es) | Procedimiento de preparacion de compuestos antagonistas del receptor cgrp e intermediarios | |
| MY139016A (en) | PYRAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF ß-ADRENERGIC RECEPTOR KINASE 1 | |
| BR0207830A (pt) | Compostos de carbamato para uso em prevenir ou tratar distúrbios de ansiedade |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |